切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2024, Vol. 18 ›› Issue (02) : 132 -136. doi: 10.3877/cma.j.issn.1674-0793.2024.02.013

综述

缺血再灌注损伤对肝细胞癌患者预后的影响及干预措施
马铭秀1, 徐锋1,()   
  1. 1. 110004 沈阳,中国医科大学附属盛京医院普通外科
  • 收稿日期:2023-08-29 出版日期:2024-04-01
  • 通信作者: 徐锋
  • 基金资助:
    辽宁省自然科学基金项目(2020-MS-181)

Impact of ischemia-reperfusion injury on the prognosis of hepatocellular carcinoma and clinical intervention choices

Mingxiu Ma1, Feng Xu1,()   

  1. 1. Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China
  • Received:2023-08-29 Published:2024-04-01
  • Corresponding author: Feng Xu
引用本文:

马铭秀, 徐锋. 缺血再灌注损伤对肝细胞癌患者预后的影响及干预措施[J/OL]. 中华普通外科学文献(电子版), 2024, 18(02): 132-136.

Mingxiu Ma, Feng Xu. Impact of ischemia-reperfusion injury on the prognosis of hepatocellular carcinoma and clinical intervention choices[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(02): 132-136.

缺血再灌注损伤(IRI)是肝脏外科常常无法回避的问题。除了引起肝功能损伤, IRI是否影响肝细胞癌患者的预后尚存争议。明确不同程度IRI 对患者预后的影响以及恰当的防治策略,对选择合适的手术方案与预防手段具有重要意义。本文就肝细胞癌相关的IRI 临床研究进展与干预措施展开综述。

Ischemia-reperfusion injury (IRI), a common issue in liver surgeries, is often difficult to be avoided.Apart from inducing liver functional impairment, the impact of IRI on the prognosis of patients with hepatocellular carcinoma (HCC) remains a subject of controversy.It is of vital significance to ascertain the effects of varying degrees of IRI in patient prognosis and to establish appropriate prevention and treatment strategies, which play pivotal roles in selecting suitably surgical approaches and preventive measures.This article provides a comprehensive review of the clinical research progress and intervention measures related to IRI in HCC cases.

[1]
Famularo S, Giani A, Di Sandro S, et al.Does the Pringle maneuver affect survival and recurrence following surgical resection for hepatocellular carcinoma? A Western series of 441 patients[J].J Surg Oncol, 2018, 117(2): 198-206.
[2]
Al-Saeedi M, Ghamarnejad O, Khajeh E, et al.Pringle maneuver in extended liver resection: A propensity score analysis[J].Sci Rep,2020, 10(1): 8847.
[3]
Lee KF, Chong C, Cheung S, et al.Impact of intermittent pringle maneuver on long-term survival after hepatectomy for hepatocellular carcinoma: result from two combined randomized controlled trials[J].World J Surg, 2019, 43(12): 3101-3109.
[4]
Lin N, Li J, Ke Q, et al.Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review[J].PLoS One, 2020, 15(3):e0229870.
[5]
Wassmer CH, Moeckli B, Berney T, et al.Shorter survival after liver pedicle clamping in patients undergoing liver resection for hepatocellular carcinoma revealed by a systematic review and meta-analysis[J].Cancers (Basel), 2021, 13(4): 637.
[6]
Jiang JH, Wang KX, Zhu JY, et al.Comparison of hepatectomy with or without hepatic inflow occlusion in patients with hepatocellular carcinoma: A single-center experience[J].Minerva Med, 2017,108(4): 324-333.
[7]
Li HH, Ma L, Xiang BD, et al.Comparison of the effect on the prognosis of HCC in terms of different surgical approaches for hepatic inflow occlusion[J].Transl Cancer Res, 2019, 8(4): 1506-1516.
[8]
黄正锋, 黄文文, 李立志, 等.Pringle 法和选择性半肝阻断法对肝细胞癌患者术后预后的影响[J].广西医学, 2019, 41(10):1262-1267.
[9]
刘建伟, 夏勇, 武烨晔, 等.不同肝门阻断方式对肝细胞癌预后的影响[J].肝胆外科杂志, 2021, 29(4): 265-270.
[10]
Liu J, Wang W, Shi C, et al.The difference in prolonged continuous and intermittent Pringle maneuver during complex hepatectomy for hepatocellular carcinoma patients with chronic liver disease:A retrospective cohort study[J].Cancer Med, 2021, 10(23): 8507-8517.
[11]
Huang Y, Liao A, Pu X, et al.A randomized controlled trial of effect of 15- or 25-minute intermittent Pringle maneuver on hepatectomy for hepatocellular carcinoma[J].Surgery, 2022,171(6): 1596-1604.
[12]
Liu S, Li X, Li H, et al.Longer duration of the Pringle maneuver is associated with hepatocellular carcinoma recurrence following curative resection[J].J Surg Oncol, 2016, 114(1): 112-118.
[13]
Xu W, Xu H, Yang H, et al.Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection[J].Asia Pac J Clin Oncol, 2017, 13(5):e321-e330.
[14]
Nagai S, Yoshida A, Facciuto M, et al.Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation[J].Hepatology, 2015, 61(3): 895-904.
[15]
Grąt M, Krawczyk M, Wronka KM, et al.Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation[J].Sci Rep, 2018, 8(1): 8935.
[16]
Shen L, Uz Z, Verheij J, et al.Interpatient heterogeneity in hepatic microvascular blood flow during vascular inflow occlusion (Pringle manoeuvre)[J].Hepatobiliary Surg Nutr, 2020, 9(3): 271-283.
[17]
Liu H, Man K.New insights in mechanisms and therapeutics for short- and long-term impacts of hepatic ischemia reperfusion injury post liver transplantation[J].Int J Mol Sci, 2021, 22(15):8210.
[18]
Schlegel A, Muller X, Kalisvaart M, et al.Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation[J].J Hepatol, 2019, 70(1): 50-57.
[19]
Cho JY, Han HS, Choi Y, et al.Association of remnant liver ischemia with early recurrence and poor survival after liver resection in patients with hepatocellular carcinoma[J].JAMA Surg,2017, 152(4): 386-392.
[20]
Ito T, Nakamura K, Kageyama S, et al.Impact of rifaximin therapy on ischemia/reperfusion injury in liver transplantation: A propensity score-matched analysis[J].Liver Transpl, 2019, 25(12):1778-1789.
[21]
Huang Y, Xu L, Wang N, et al.Preoperative Dexamethasone administration in hepatectomy of 25-minute intermittent Pringle's maneuver for hepatocellular carcinoma: A randomized controlled trial[J].Int J Surg, 2023.
[22]
Feng C, Qian D, Chen C.A meta-analysis and systematic review of Propofol on liver ischemia-reperfusion injury protection during hepatocellular carcinoma anesthesia surgery[J].Ann Palliat Med,2021, 10(6): 6726-6735.
[23]
Koraki E, Mantzoros I, Chatzakis C, et al.Metalloproteinase expression after Desflurane preconditioning in hepatectomies: A randomized clinical trial[J].World J Hepatol, 2020, 12(11): 1098-1114.
[24]
Jakubauskiene L, Jakubauskas M, Stiegler P, et al.Ischemic preconditioning for liver transplantation: A systematic review and meta-analysis of randomized controlled trials[J].Visc Med, 2021,37(5): 329-337.
[25]
Jung KW, Kang J, Kwon HM, et al.Effect of remote ischemic preconditioning conducted in living liver donors on postoperative liver function in donors and recipients following liver transplantation: A randomized clinical trial[J].Ann Surg, 2020,271(4): 646-653.
[26]
Liu TS, Shen QH, Zhou XY, et al.Application of controlled low central venous pressure during hepatectomy: A systematic review and meta-analysis[J].J Clin Anesth, 2021, 75: 110467.
[27]
Yang P, Gao S, Chen X, et al.Milrinone is better choice for controlled low central venous pressure during hepatectomy: A randomized, controlled trial comparing with nitroglycerin[J].Int J Surg, 2021, 94: 106080.
[28]
Kornberg A, Witt U, Kornberg J, et al.Treating ischaemiareperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation[J].Aliment Pharmacol Ther, 2015, 42(9): 1101-1110.
[29]
Hu C, Zhao L, Zhang F, et al.Melatonin and its protective role in attenuating warm or cold hepatic ischaemia/reperfusion injury[J].Cell Prolif, 2021, 54(4): e13021.
[30]
Khajeh E, Moghadam AD, Eslami P, et al.Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery[J].BMC Cancer, 2022, 22(1): 91.
[1] 姚宏伟, 孙丽婷. 腹腔镜中低位直肠癌新辅助放化疗联合免疫治疗后根治性保肛术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 132-132.
[2] 张忠涛, 高加勒, 姚宏伟. 新辅助放化疗联合免疫治疗局部进展期直肠癌的现状与前景[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 119-122.
[3] 姚宏伟, 孙丽婷, 吴偲, 舒文龙, 高加勒, 杨正阳, 吴国聪, 张忠涛. 新辅助放化疗联合免疫治疗局部进展期直肠癌的探索与实践[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 123-127.
[4] 王乾宇, 杜峻峰, 李世拥. 新辅助放化疗联合免疫治疗局部进展期直肠癌的突破与挑战[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 128-131.
[5] 肖建, 肖天保, 陈江, 杨桃, 何峰, 保甜甜, 曹一波, 杨琴, 赵颖. 吲哚菁绿成像技术在保留左结肠动脉的直肠癌根治术中的应用价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 134-137.
[6] 韦洋, 赵远权, 王小波, 黄海, 陈洁. BCLC 0/A期肝细胞癌患者术后辅助治疗后早期复发风险分析及预测模型建立[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 157-161.
[7] 艾世超, 孙艺文, 宋鹏, 沈晓菲, 刘颂, 孙锋, 陆晓峰, 王萌, 管文贤. 静脉注射吲哚菁绿导航胃癌根治术的单臂开放前瞻性研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 166-169.
[8] 李峥, 马晋峰. 基于炎症反应评分系统构建预测根治性术后食管胃结合部腺癌患者预后的列线图模型[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 170-175.
[9] 何友新, 韩林荟, 杨贺庆. 新辅助化疗分别联合保乳术和改良根治术治疗Ⅱ、Ⅲ期乳腺癌的应用效果[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 184-187.
[10] 董家旭, 宋美姿, 毕讯. 射频消融术联合TSH抑制治疗甲状腺微小乳头状癌的效果及生存预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 200-203.
[11] 孙建, 赵明慧, 赵恩春, 刘威辰. 经胸乳入路腔镜手术治疗甲状腺癌的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 204-207.
[12] 潘银珍, 张秀玉, 麦燕桃, 梁智强. 两种术式治疗肝内胆管细胞癌的临床疗效研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 208-211.
[13] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[14] 徐涵治, 邱洵, 汪恺, 徐骁. 脂肪变性供肝脱脂策略的研究[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 18-24.
[15] 吴哲境, 李敬东, 熊永福, 刘刚, 陈雷. 吲哚菁绿在解剖性肝切除术中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 25-29.
阅读次数
全文


摘要